PMC9751182_01
The levels of human growth hormone (HGH, normal range: 0-2.47 ng/mL; A) and insulin-like growth factor 1 (IGF-1, normal range: 94-284 mug/L; B) of the acromegalic patient with the treatment of Sandostatin LAR in recent 3 years.
fpsyt-13-1068836-g001.jpg
PMC9751182_01_fpsyt-13-1068836-g001.jpg
F1
The patient received the injection of Sandostatin LAR 10 mg per month with regularly monitoring of GH/IGF-1 levels (Figure 1) and pituitary MRI (Figure 2) at Department of Endocrinology of the same hospital.
The maximum cross-sectional area (mm2) of the pituitary macroadenoma measured by pituitary magnetic resonance imaging (MRI) of the acromegalic patient with the treatment of Sandostatin LAR in recent 3 years.
fpsyt-13-1068836-g002.jpg
PMC9751182_01_fpsyt-13-1068836-g002.jpg
F2
The patient received the injection of Sandostatin LAR 10 mg per month with regularly monitoring of GH/IGF-1 levels (Figure 1) and pituitary MRI (Figure 2) at Department of Endocrinology of the same hospital.
The magnetic resonance imaging (MRI) of coronal (left) and sagittal (right) sections showing a pituitary macroadenoma. Specifically, the maximum cross-sectional area was 42 mm x 37 mm, which had compressed the optical chiasm, invaded the skull base bone, and surrounded blood vessels in sellar area.
fpsyt-13-1068836-g003.jpg
PMC9751182_01_fpsyt-13-1068836-g003.jpg
F3
Furthermore, his frontal bone, parietal bone and occipital bone were detected diffusely thickening and ballooning (Figure 3).